Parallel trade of pharmaceutical products : the ECJ finally speaks — comment on GlaxoSmithKline

Petrucci, C 2010, 'Parallel trade of pharmaceutical products : the ECJ finally speaks — comment on GlaxoSmithKline' , European Law Review (2) , pp. 275-286.

PDF - Published Version Restricted to Repository staff only Download (322kB)

Abstract

This article reviews the ECJ’s judgment in GlaxoSmithKline that overturned some important findings of the CFI’s decision. It criticises the longstanding problematic distinction between anti-competitive object and effect and, in particular, whether distribution agreements that limit parallel trade fit into the category of agreement having an anti-competitive object. Given that the ECJ’s decision reasserted a multi-goal approach to EU competition law, it is argued that the judgment leaves some issues unresolved. Similarly, the issues of the effects of price regulation and research and development (R&D) funding have not been dealt with adequately.

Item Type:	Article
Themes:	Subjects outside of the University Themes
Schools:	Schools > Salford Business School > Salford Business School Research Centre
Journal or Publication Title:	European Law Review
Publisher:	Sweet & Maxwell
Refereed:	Yes
ISSN:	0307-5400
Depositing User:	Mr Carlo Petrucci
Date Deposited:	15 Nov 2011 10:32
Last Modified:	16 Feb 2022 13:35
URI:	https://usir.salford.ac.uk/id/eprint/18980

Actions (login required)

Edit record (repository staff only)